Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07204249 · ClinicalTrials.gov registry record · Phase 2
Glutide for Ending Methamphetamine
A Phase 2 study, sponsored by San Francisco Department of Public Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT07204249 is a Phase 2 study that is actively recruiting participants, run by San Francisco Department of Public Health. The registered enrollment target is 162 participants.
The verdict
NCT07204249, a Phase 2 study, is actively recruiting participants, sponsored by San Francisco Department of Public Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD. The second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.
Interventions
- DRUG Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2030-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07204249
The ClinicalTrials.gov registry entry for NCT07204249 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is San Francisco Department of Public Health, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07204249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07204249 about?
NCT07204249 is a clinical study titled "Glutide for Ending Methamphetamine". GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, ...
What is the current status of trial NCT07204249?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2026-02-26. Estimated completion is 2030-02-15.
What interventions are being tested in trial NCT07204249?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07204249?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.